JPWO2019147973A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019147973A5 JPWO2019147973A5 JP2020561607A JP2020561607A JPWO2019147973A5 JP WO2019147973 A5 JPWO2019147973 A5 JP WO2019147973A5 JP 2020561607 A JP2020561607 A JP 2020561607A JP 2020561607 A JP2020561607 A JP 2020561607A JP WO2019147973 A5 JPWO2019147973 A5 JP WO2019147973A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid position
- tyrosine
- binding polypeptide
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000001014 amino acid Nutrition 0.000 claims 121
- 150000001413 amino acids Chemical group 0.000 claims 121
- 229920001184 polypeptide Polymers 0.000 claims 54
- 102000004196 processed proteins & peptides Human genes 0.000 claims 54
- 108090000765 processed proteins & peptides Proteins 0.000 claims 54
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 44
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 44
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 20
- 235000003704 aspartic acid Nutrition 0.000 claims 19
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 19
- 238000006467 substitution reaction Methods 0.000 claims 14
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 13
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 13
- 230000002378 acidificating effect Effects 0.000 claims 13
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 12
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 11
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 11
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 8
- 235000013922 glutamic acid Nutrition 0.000 claims 8
- 239000004220 glutamic acid Substances 0.000 claims 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 7
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 7
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 6
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 4
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 3
- 239000004473 Threonine Substances 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims 1
- 229930010555 Inosine Natural products 0.000 claims 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101000913100 Rattus norvegicus IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960003786 inosine Drugs 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023204313A JP2024026255A (ja) | 2018-01-26 | 2023-12-04 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
| JP2025179195A JP2026021377A (ja) | 2018-01-26 | 2025-10-24 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622468P | 2018-01-26 | 2018-01-26 | |
| US62/622,468 | 2018-01-26 | ||
| PCT/US2019/015204 WO2019147973A1 (en) | 2018-01-26 | 2019-01-25 | Fc variants with enhanced binding to fcrn and prolonged half-life |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023204313A Division JP2024026255A (ja) | 2018-01-26 | 2023-12-04 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021511830A JP2021511830A (ja) | 2021-05-13 |
| JP2021511830A5 JP2021511830A5 (https=) | 2022-02-01 |
| JPWO2019147973A5 true JPWO2019147973A5 (https=) | 2022-02-01 |
| JP7399880B2 JP7399880B2 (ja) | 2023-12-18 |
Family
ID=65520379
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561607A Active JP7399880B2 (ja) | 2018-01-26 | 2019-01-25 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
| JP2023204313A Pending JP2024026255A (ja) | 2018-01-26 | 2023-12-04 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
| JP2025179195A Pending JP2026021377A (ja) | 2018-01-26 | 2025-10-24 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023204313A Pending JP2024026255A (ja) | 2018-01-26 | 2023-12-04 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
| JP2025179195A Pending JP2026021377A (ja) | 2018-01-26 | 2025-10-24 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190263934A1 (https=) |
| EP (1) | EP3743441A1 (https=) |
| JP (3) | JP7399880B2 (https=) |
| KR (2) | KR102748986B1 (https=) |
| CN (2) | CN111788221B (https=) |
| AU (2) | AU2019212638B2 (https=) |
| BR (1) | BR112020015006A2 (https=) |
| CA (1) | CA3089602A1 (https=) |
| CO (1) | CO2020010269A2 (https=) |
| IL (2) | IL318916A (https=) |
| MX (2) | MX2020007882A (https=) |
| MY (1) | MY203898A (https=) |
| PH (1) | PH12020551134A1 (https=) |
| SG (1) | SG11202006905YA (https=) |
| TW (1) | TW201940512A (https=) |
| WO (1) | WO2019147973A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7399880B2 (ja) * | 2018-01-26 | 2023-12-18 | ジェンザイム・コーポレーション | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
| EP4004039A2 (en) * | 2019-07-25 | 2022-06-01 | Genzyme Corporation | Methods of treating antibody-mediated disorders with fcrn antagonists |
| CN114746120B (zh) | 2019-10-03 | 2024-07-30 | Atyr医药公司 | 包含抗nrp2抗体的组合物和方法 |
| US11434276B2 (en) * | 2020-05-11 | 2022-09-06 | Invetx, Inc. | Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use |
| MX2023004933A (es) * | 2020-10-29 | 2023-06-06 | Formycon Ag | Proteinas de fusion de ace2 y usos de las mismas. |
| US12297273B2 (en) | 2021-05-27 | 2025-05-13 | Sanofi | Fc variant with enhanced affinity to Fc receptors and improved thermal stability |
| MX2024002150A (es) | 2021-08-20 | 2024-03-08 | Intervet Int Bv | Anticuerpos y proteinas de fusion de igg con una semivida prolongada. |
| WO2023244276A2 (en) * | 2021-10-13 | 2023-12-21 | The Wistar Institute Of Anatomy And Biology | DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS |
| IL317227A (en) | 2022-05-27 | 2025-01-01 | Sanofi Sa | Combined natural killer (NK) cells bind to NKP46 and BCMA variants with FC engineering |
| CN116162171B (zh) * | 2022-10-13 | 2025-06-03 | 深圳市百士通科技开发有限公司 | 抗体突变方法在治疗性抗体药物中的应用 |
| KR20250094703A (ko) | 2022-10-25 | 2025-06-25 | 아블린쓰 엔.브이. | 향상된 효과기 기능을 갖는 당조작된 Fc 변이체 폴리펩타이드 |
| AR131281A1 (es) | 2022-12-05 | 2025-03-05 | Sanofi Sa | Proteínas de unión al receptor de transferrina |
| US20250154262A1 (en) | 2023-10-25 | 2025-05-15 | Ablynx N.V. | Fc DOMAIN VARIANTS WITH ENHANCED Fc RECEPTOR BINDING |
| WO2025101094A1 (en) * | 2023-11-08 | 2025-05-15 | Ооо «Geropharm» | Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates |
| WO2025149633A1 (en) | 2024-01-12 | 2025-07-17 | Laigo Bio B.V. | Bispecific antigen binding proteins |
| WO2026022712A1 (en) | 2024-07-23 | 2026-01-29 | Sanofi | Cereblon ligase modulator and bcma nk cell engager combination therapy |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| HU230769B1 (hu) * | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
| CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
| KR20070057839A (ko) * | 2004-08-19 | 2007-06-07 | 제넨테크, 인크. | 변경된 이펙터 기능을 갖는 폴리펩티드 변이체 |
| DK1817340T3 (da) | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP2373689A1 (en) * | 2008-12-12 | 2011-10-12 | MedImmune, LLC | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
| HRP20160422T1 (hr) * | 2009-12-23 | 2016-05-20 | Synimmune Gmbh | Protutijela protiv flt3 postupci njihove upotrebe |
| WO2011089211A1 (en) * | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
| TWI588156B (zh) | 2011-03-28 | 2017-06-21 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| JP6322411B2 (ja) * | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| RU2687043C2 (ru) * | 2013-04-29 | 2019-05-06 | Ф. Хоффманн-Ля Рош Аг | МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| RS59340B1 (sr) * | 2014-11-06 | 2019-10-31 | Hoffmann La Roche | Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe |
| EP3218402A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Anti-il-1beta antibodies and methods of use |
| SG11201900616UA (en) * | 2016-08-02 | 2019-02-27 | Visterra Inc | Engineered polypeptides and uses thereof |
| JP7399880B2 (ja) * | 2018-01-26 | 2023-12-18 | ジェンザイム・コーポレーション | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
-
2019
- 2019-01-25 JP JP2020561607A patent/JP7399880B2/ja active Active
- 2019-01-25 SG SG11202006905YA patent/SG11202006905YA/en unknown
- 2019-01-25 CN CN201980015900.4A patent/CN111788221B/zh active Active
- 2019-01-25 WO PCT/US2019/015204 patent/WO2019147973A1/en not_active Ceased
- 2019-01-25 IL IL318916A patent/IL318916A/en unknown
- 2019-01-25 BR BR112020015006-1A patent/BR112020015006A2/pt unknown
- 2019-01-25 TW TW108102958A patent/TW201940512A/zh unknown
- 2019-01-25 MX MX2020007882A patent/MX2020007882A/es unknown
- 2019-01-25 EP EP19707152.5A patent/EP3743441A1/en active Pending
- 2019-01-25 AU AU2019212638A patent/AU2019212638B2/en active Active
- 2019-01-25 US US16/258,080 patent/US20190263934A1/en active Pending
- 2019-01-25 KR KR1020207024432A patent/KR102748986B1/ko active Active
- 2019-01-25 IL IL276286A patent/IL276286B2/en unknown
- 2019-01-25 CA CA3089602A patent/CA3089602A1/en active Pending
- 2019-01-25 KR KR1020247043107A patent/KR20250008975A/ko active Pending
- 2019-01-25 CN CN202411307275.XA patent/CN119350481A/zh active Pending
- 2019-01-25 MY MYPI2020003848A patent/MY203898A/en unknown
-
2020
- 2020-07-24 MX MX2025009543A patent/MX2025009543A/es unknown
- 2020-07-24 PH PH12020551134A patent/PH12020551134A1/en unknown
- 2020-08-20 CO CONC2020/0010269A patent/CO2020010269A2/es unknown
-
2023
- 2023-12-04 JP JP2023204313A patent/JP2024026255A/ja active Pending
-
2025
- 2025-06-26 AU AU2025204826A patent/AU2025204826A1/en active Pending
- 2025-10-24 JP JP2025179195A patent/JP2026021377A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024026255A5 (https=) | ||
| JP2021511830A5 (https=) | ||
| IL276286B1 (en) | FC variants with improved binding to FCRN and extended half-life | |
| JPWO2019147973A5 (https=) | ||
| CN108350048B (zh) | 具有SIRP-α结构域或其变体的构建体 | |
| JP7533898B2 (ja) | 血中半減期の向上のための抗体Ｆｃ変異体 | |
| CN110520445B (zh) | 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备 | |
| KR102247704B1 (ko) | 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법 | |
| JPWO2020116560A1 (ja) | 抗体のＦｃ領域改変体 | |
| JP7050838B2 (ja) | ＦｃＲｎ相互作用が変更された抗体を選択するための方法 | |
| JP7829489B2 (ja) | ヘテロ二量体Ｆｃポリペプチド | |
| CN118063619A (zh) | 工程化的异源二聚体蛋白质 | |
| JP2025098167A5 (https=) | ||
| US20200369719A1 (en) | Depletion of Light Chain Mispaired Antibody Variants By Hydrophobic Interaction Chromatography | |
| JP2020503873A (ja) | 多重特異的抗体を調製するためのポリペプチドリンカー | |
| CN1946741A (zh) | 金结合蛋白及其用途 | |
| TW202233694A (zh) | 雙特異性抗體 | |
| JP7792044B2 (ja) | ヒト化抗ｉｌ－１ｒ３抗体及び使用方法 | |
| CN116583300A (zh) | 多特异性抗原结合蛋白 | |
| TW202506723A (zh) | 結合fcrn之fc片段及使用方法 | |
| JPWO2015050153A1 (ja) | 免疫グロブリンＧ（ＩｇＧ）のＦｃ部分を有するタンパク質に対するアフィニティを有する複数のドメイン間をリンカーで結合させて成るタンパク質 | |
| WO2023072217A1 (en) | Fusion proteins targeting cd3 and cd47 | |
| CA3229430A1 (en) | Anti-vegfr1 antibodies and their uses | |
| TW202204423A (zh) | 用於產生和純化多價免疫球蛋白單可變域的方法 | |
| JP7796415B2 (ja) | エリスロポエチンポリペプチドを含む融合タンパク質 |